trending Market Intelligence /marketintelligence/en/news-insights/trending/1hksjr_6lbiqkn-kfxczja2 content esgSubNav
In This List

US FDA issues warning to Bayer over drug manufacturing violations

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


US FDA issues warning to Bayer over drug manufacturing violations

The U.S. Food and Drug Administration issued a warning letter to Bayer AG over violations at its drug manufacturing facility in Leverkusen, Germany, Reuters reported.

The German pharmaceutical company is addressing the concerns raised by the regulator.

Bayer is expecting temporary supply limitations that will affect its blood pressure drug Adalat, blood thinner Aspirin Cardio, antibiotic Avelox and potency drug Levitra.

The company will quantify the impact in its upcoming 2018 guidance on Feb. 28.